# Allarity Therapeutics, Inc. (ALLR) · Edgar & Edgarette company card

> Allarity Therapeutics (ALLR) reported revenue of $0 million in FY2025, operating margin -3939% against a -3.8% median for pharmaceutical preparations, equity 53.8% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1860657 · fiscal year ended 2025-12-31 · 2 audited years read · [page](https://www.pops4.com/boards/company/ALLR) · [JSON](https://www.pops4.com/boards/company/ALLR.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $320,000 |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | -3939.1% (prior year -Infinity%) |
| Net margin | -3509.7% |
| Operating cash flow | −$15M |
| Capital spending | $8,000 |
| Free cash flow | −$15M |
| Cash | $15M |
| Long-term debt | — |
| Total assets | $18M |
| Total equity | $10M |
| Equity ÷ assets | 53.8% |
| Return on equity | -114.3% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -23.25 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative (-$14.8M in FY2025); operating loss: a margin of -3939.1% in FY2025

## Edgarette's reading

Exposure: revenue $320K (FY2025). Experience: one year on record; operating margin -3939.1%, up from null. Soundness: equity 53.8% of assets, return on equity -114.3%. Credibility: 2 audited years, moderate weight. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -3939.1% against a -3.8% median.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-06-02 ([filing](https://www.sec.gov/Archives/edgar/data/1860657/000121390026064278/0001213900-26-064278-index.htm))

## Recent filings

- 8-K · filed 2026-11-02 · 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1860657/000121390026114682/0001213900-26-114682-index.htm)
- 8-K · filed 2026-10-30 · 1.02 Termination of a Material Definitive Agreement · [filing](https://www.sec.gov/Archives/edgar/data/1860657/000121390026114380/0001213900-26-114380-index.htm)
- 8-K · filed 2026-10-01 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1860657/000121390026105457/0001213900-26-105457-index.htm)
- 8-K · filed 2026-09-29 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1860657/000121390026104317/0001213900-26-104317-index.htm)
- 8-K · filed 2026-09-16 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1860657/000121390026100350/0001213900-26-100350-index.htm)
- 8-K · filed 2026-09-14 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1860657/000121390026099576/0001213900-26-099576-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001860657.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1860657

## Cite

POPS4, Edgar & Edgarette: Allarity Therapeutics, Inc. (ALLR) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/ALLR. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.